|
||||||
Lybrel is a new combined contraceptive pill that promises to put an end to painful periods and PMT. This article looks at how it works, and the pros and cons of using it.
Lybrel is the first continuous use drug designed to prevent pregnancy. It was approved by the FDA (US Food & Drug Administration) in 2007 and should be available in the UK this year. How Do You Use Lybrel?It comes in a 28-day pack and contains a low dose combination of oestrogen and progestogen. It works in the same way as other contraceptive pills, by lowering the production of hormones that enable pregnancy. It is currently available on prescription only. Why The Big Fuss?It puts a woman in control of her body and gives her a choice as to whether she wants to have a period or not. An estimated 3.5m women in the UK currently use the contraceptive pill and many take it continuously to avoid painful and heavy periods or to delay them at inconvenient times. Several British papers hailed it as the new ‘super pill’ and it’s an important development in oral contraception. How Effective Is Lybrel? Two one-year clinical studies were carried out, using 2,400+ women, aged between 18-49. In the primary study, 59% of women who took it for one year had no bleeding or spotting during the final month. Wyeth Pharmaceuticals (the manufacturer) say spotting should decrease over time as the body gets used to taking it. However, the NHS National Library of Health reports that only 43% of the women completed the trial because of side effects such as headaches, breast pain and sickness. Studies suggest it is 92-99.7% effective, like other forms of oral contraceptive. Pros of Using Lybrel
Cons of Using Lybrel
ReferencesThe Great Escape: Ending Period Pain, New Scientist magazine, issue 2623, September 26, 2007, pg 40-43.
The copyright of the article Lybrel - The New Super Pill in Women's Sexual Health is owned by Nicci Talbot. Permission to republish Lybrel - The New Super Pill in print or online must be granted by the author in writing.
|
||||||
|
|
||||||
|
|
||||||